Objective: This review was conducted to provide information on nonstimulant medications used to treat ADHD. Method: Previous investigations on several groups of nonstimulant medications were reviewed, and a discussion of antidepressants, antihypertensives, atypical antipsychotics, anticonvulsants, and cholinergic agents is included. Results: The results of this review provide information on several viable options of treatment in situations in which the use of a stimulant would be inappropriate or in situations in which stimulants have provided limited effectiveness. Conclusion: Despite their viability as alternatives, each type of medication has certain limitations, side effects, and varying amounts of research available to substantiate its use for the treatment of ADHD. These medications offer several potentially successful options to those who fail to respond to stimulants or to those who find the side effects of stimulants bothersome. (J. of Att. Dis. 2007; 11(3) 341-350)
Abikoff, H., McGough, J., Vitiello, B., McCracken, J., Davies, M., Walkup, J., et al. (2005). Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 44, 418-427.
2.
Adler, L., Resnick, S., Kunz, M., & Devinsky, O. (1995). Open label trial of venlafaxine in adults with attention deficit disorder. Psychopharmacological Bulletin , 31, 785-788.
3.
Aman, M.G., Armstrong, S., Buican, B., & Sillick, T. (2002). Four-year follow-up of children with low intelligence and ADHD: A replication. Research in Developmental Disabilities , 23, 119-134.
4.
American Psychiatric Association. (2003). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author .
Banaschewski, T., Roessner, V., Dittman, R.W., Santosh, P.J., & Rothenberger, A. (2004). Non-stimulant medications in the treatment of ADHD. European Child & Adolescent Psychiatry, 13(Suppl 1), 102-116.
7.
Barkley, R.A. (2004). Adolescents with attention-deficit/hyperactivity disorder: An overview of empirically based treatments. Journal of Psychiatric Practice, 10, 39-56.
8.
Barkley, R., McMurray, M., Edelbrock, C., & Robbins, K. (1990). Side effects of methylphenidate in children with attention deficit hyperactivity disorder: A systemic, placebo-controlled evaluation . Pediatrics, 86, 184-192.
9.
Barrickman, L., Noyes, R., Kuperman, S., Schumacher, E., & Verda, M. (1991). Treatment of ADHD with fluoxetine: A preliminary trial. Journal of the American Academy of Child and Adolescent Psychiatry, 30(5), 762-767.
10.
Barrickman, L., Perry, P.J., Allen, A.J., Kuperman, S., Arndt, S.V., & Herrmann, K.J. (1995). Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. Journal of American Academy of Children and Adolescents Psychiatry, 34, 649-657.
11.
Bymaster, F., Katner, J., Nelson, D., Hemrick-Luecke, S., Threlkeld, P., Heiligenstein, J., et al. (2002). Atomoxetine increases extracellular levels of norepinephrine and dopamine in the prefrontal cortex of the rat: A potential mechanism for efficacy in attention-deficit hyperactivity disorder. American Journal of Neuropsychopharmacology,27, 699-711.
12.
Carlson, G.A., Rapport, M.D., Kelly, K.L., & Pataki, C.S. (1995). Methylphenidate and desipramine in hospitalized children with comorbid behavior and mood disorders: Separate and combined effects on behavior and mood. Journal of Child and Adolescent Psychopharmacology, 5, 191-204.
13.
Chappell, P.B., Riddle, M.A., Scahill, L., Lynch, K.A., Schultz, R., & Arnsten, A. (1995). Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: Preliminary clinical experience . Journal of the American Academy of Child and Adolescent Psychiatry, 34, 1140-1146.
14.
Conners, C., Casat, C., Gualtieri, C., Weller, E., Reader, M., & Reiss, A. (1996). Bupropion hydrochloride in attention deficit disorder with hyperactivity. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 1314-1321.
15.
Connor, D., Barkley, R., & Davis, H. (2000). A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clinical Pediatrics, 39, 15-25.
16.
Daviss, W., Bentivoglio, P., Racusin, R., Brown, K., Bostic, J., & Wiley, L. (2001). Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression. Journal of the American Academy of Child and Adolescent Psychiatry,40, 307-314.
17.
DeVeaugh-Geiss, J., Conners, C.K., Sarkis, E.H., Winner, P.K., Ginsberg, L.D., & Hemphill, J. (2002). GW320659 for the treatment of attention-deficit/hyperactivity disorder in children. Journal of American Academy of Children and Adolescent Psychiatry, 41, 914-920.
18.
DuPaul, G., Barkley, R., & Connor, D. (1998). Stimulant medications for ADHD children. In R. Barkley (Ed.), Attention deficit hyperactivity disorder: A handbook for diagnosis and treatment (2nd ed., pp. 510-551). New York: Guilford.
19.
DuPaul, G., & Stoner, G. (2003). ADHD in the schools: Assessment and intervention strategies. (2nd ed.). New York : Guilford.
20.
Elia, J., Borcherding, B., Rapoport, J., & Keysor, C. (1991). Methylphenidate and dextroamphetamine treatments of hyperactivity: Are there true nonresponders?Psychiatric Research, 36, 141-155.
21.
Emslie, G., Walkup, J., Pliszka, S., & Ernst, M. (1999). Nontricyclic antidepressants: Current trends in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 517-532.
22.
Fankhauser, M., Karumanchi, V., German, M., Yates, A., & Karumanchi, S. (1992). A double blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. Journal of Clinical Psychiatry, 53, 77-82.
23.
Fava, M., Hoog, S., Rajinder, J., Kopp, J., Nilsson, M., & Gonzales, J. (2002). Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia. Journal of Clinical Psychopharmacology, 22, 137-142.
24.
Fenichel, R. (1995). Combining methylphenidate and clonidine: The role of post-marketing surveillance. Journal of Child and Adolescent Psychopharmacology, 5, 155-156.
25.
Findling, R. (1996). Open-label treatment of comorbid depression and attentional disorders with co-administration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: A case series. Journal of Child and Adolescent Psychopharmacology, 6, 165-175.
26.
Findling, R., Schwartz, M., Flannery, D., & Manos, M. (1997). Venlafaxine in adults with attention-deficit hyperactivity disorder: An open clinical trial. Journal of Clinical Psychiatry , 58, 178-179.
27.
Galanter, C., Bilich, C., & Walsh, T. (2002). Side effects of desipramine and age. Journal of Child and Adolescent Psychopharmacology, 12, 137-145.
28.
Garland, E.J. (2003). Use of venlafaxine in child and adolescent psychiatry . Child and Adolescent Psychopharmacology News, 8, 1-4.
29.
Geller, B., Reising, D., Leonard, H., Riddle, M.A., & Walsh, T. (1999). Critical review of tricyclics antidepressant use in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 513-516.
30.
Gitlin, M. (1996). The psychotherapist's guide to psychopharmacology (2nd ed.). New York: Free Press.
31.
Green, W. (1995). Child and adolescent clinical psychopharmacology . Baltimore: Williams & Wilkins .
32.
Greenhill, L.L. (1992). Pharmacologic treatment of attention deficit hyperactivity disorder. Psychiatric Clinics of North America, 15, 1-27.
33.
Groh, C. (1976). The psychotropic effect of tegretol in non-epileptic children, with particular reference to the drug's indications. In W. Birkmayer (Ed.), Epileptic seizures behaviour-pain (pp. 259-263). Vienna: University Park Press.
34.
Gualtieri, T.C., & Evans, R.W. (1988). Motor performance in hyperactive children treated with Imipramine. Perceptual and Motor Skills, 66, 763-769.
35.
Hazell, P.L., & Stuart, J.E. (2003). A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. Journal of the American Academy of Child & Adolescent Psychiatry, 42(8), 886.
36.
Hedges, D., Reimherr, F., Rogers, A., Strong, R., & Wender, P. (1995). An open label trial of venlafaxine in adult patients with attention deficit disorder. Psychopharmacological Bulletin , 31, 779-783.
37.
Horrigan, J.P., & Barnhill, L.J. (1995). Guanfacine for the treatment of attention-deficit hyperactivity disorder in boys. Journal of Child and Adolescent Psychopharmacology, 5, 215-223.
38.
Horst, W.D., & Preskorn, S.H. (1998). Mechanisms of actions and clinical characteristics of three atypical antidepressants: Venlafaxine, nefazodone, and bupropion. Journal of Affective Disorders, 51, 237-254.
39.
Hunt, R.D., Arnsten, A.F., & Asbell, M.D. (1995). An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. Journal of American Academy of Child and Adolescent Psychiatry, 34, 50-54.
40.
Jadad, A., Boyle, M., Cunningham, C., Kim, M., & Schachar, R. (1998). The treatment of attention-deficit/hyperactivity disorder: An evidence report. Rockville, MD: U.S. Department of Health and Human Services, Agency for Healthcare Research and Quality.
41.
Jones, G.M., Sahakian, B.J., Levy, R., Warburton, D.M., & Gray, J.A. (1992). Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology (Berl), 108, 485-494.
42.
Julien, R.M. (2005). A primer of drug action: A comprehensive guide to the actions, uses, and side effects of psychoactive drugs (3rd ed.). Portland, OR: Worth.
43.
Kelsey, D., Sumner, C., Casat, D., Coury, D., Quintana, H., & Saylor, K. (2004). Once daily atomoxetine treatment for children with attention-deficit hyperactivity disorder, including an assessment of evening and morning behavior: A double-blind placebo controlled trial. Pediatrics, 114, 240.
44.
Kratochvil, C., Heiligenstein, J., Dittman, R., Spencer, T., Biederman, J., Wernicke, J., et al. (2002). Atomoxetine and methyphenidate treatment in children with ADHD: A perspective, randomized open-label trial. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 776-784.
45.
Kratochvil, C., Wilens, T., Greenhill, L., Gao, H., Baker, K., Feldman, P., et al. (2006). Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 919-927.
46.
Krausz, M. (2002). Efficacy review of antipsychotics. Current Medical Research Opinion, 18(Suppl. 3), s8-s12.
47.
Leckman, J., Hardin, M., Riddle, M., Stevenson, J., Ort, S., & Cohen, D. (1991). Clonidine treatment of Gilles de la Tourette's syndrome. Archives of General Psychiatry, 48, 324-328.
48.
Levin, E.D., Conners, C.K., Sparrow, E., Hinton, S.C., Erhardt, D., Meck, W.H., et al. (1996). Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl), 123, 55-63.
49.
Levitas, A., & Hurley, A. (2005) The SSRI controversy. Mental Health Aspects of Developmental Disabilities, 8(2), 61-63.
50.
Masand, P., & Gupta, S. (1999). Selective serotonin-reuptake inhibitors: An update . Harvard Review of Psychiatry, 7(2), 69-84.
51.
Michelson, A. (2004, October). A double-blind, placebo controlled comparison of atomexetine, OROS methylphenidate, and placebo. Paper presented at the meeting of the American Academy of Child and Adolescent Psychiatry, Washington, DC.
52.
Michelson, A., & Busner, J. (2003). Once-daily atomoxetine may reduce attention-deficit hyperactivity disorder symptoms in children and adolescents. Evidence-Based Mental Health, 6, 42.
53.
Michelson, A., Busner, J., Allen, A., Casat, C., Dunn, D., Kratochvil, C., et al. (2002). Once-daily atomoxetine treatment for children and adolescents with attention-deficit hyperactivity disorder: A randomized placebo-controlled study. American Journal of Psychiatry, 159, 1896-1901.
54.
Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, R., et al. (2001). Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized placebo-controlled dose-response study. Pediatrics, 108, 1197.
55.
Mukaddes, N.M., & Abali, O. (2004). Venlafaxine in children and adolescents with attention deficit hyperactivity disorder. Psychiatry and Clinical Neurosciences , 58, 92-95.
56.
Multimodal Treatment Study of Attention Deficit/Hyperactivity Disorder Cooperative Group. (1999). A 14-month randomized clinical trial of treatment strategies for attention-deficit/ hyperactivity disorder. Archives of General Psychiatry, 56, 1073-1086.
57.
Nichols, M.L. (1994). Effects of imipramine on the cognitive, learning and academic performance of children with attention deficit hyperactivity disorder. Dissertation Abstracts International: Section B: The Sciences and Engineering, 55, 2014.
58.
Olvera, R.L., Pliszka, S.R., Luh, J., & Tatum, R. (1996). An open clinical trial of venlafaxine in the treatment of attention-deficit/ hyperactivity disorder in children and adolescents. Journal of Child and Adolescent Psychopharmacology, 6, 241.
59.
Pataki, C.S., Carlson, G.A., Kelly, K.L., Rapport, M.D., & Biancaniello, T.M. (1993). Side effects of methylphenidate and desipramine alone and in combination in children. Journal of the American Academy of Child and Adolescent Psychiatry, 32, 1065-1072.
60.
Pellock, J.M. (1987). Carbamazepine side effects in children and adults . Epilepsia, 28, S64-S70.
61.
Pliszka, S. (2000). Comparing the effects of stimulant and nonstimulant agents on catecholamine function: Implications for theories of ADHD. In M. Solanto, A. Arsten, & F. Castellanos (Eds.), Stimulant drugs and ADHD: Basic and clinical neuroscience (pp. 231-254). New York: Oxford University Press.
62.
Pliszka, S. (2003). Psychiatric comorbidities in children with attention deficit hyperactivity disorder. Pediatric Drugs, 5, 741-750.
63.
Popper, C. (1997). Antidepressants in the treatment of attention-deficit/hyperactivity disorder. Journal of Clinical Psychiatry, 58(Suppl.), 14-29.
64.
Prince, J.B., Wilens, T.E., Biederman, J., Spencer, T.J., Millstein, R., Polisner, D.A., et al. (2000). A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 10, 193-204.
65.
Prince, J., Wilens, T., Biederman, J., Spencer, T., & Wozniak, J. (1996). Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder: A systematic chart review of 62 cases. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 599-605.
66.
Rapport, M.D., Carlson, G.A., Kelly, K.L., & Pataki, C. (1993). Separate and combined effects on cognitive function . Journal of the American Academy of Child and Adolescent Psychiatry, 32, 333-340.
67.
Riggs, P., Leon, S., Mikulich, S., & Pottle, L. (1998) An open label trial of bupropion for ADHD in adolescents with substance abuse disorders and conduct disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 37, 1271-1278.
68.
Scahill, L. (1996). Nonstimulant medications in the treatment of attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychiatric Nursing, 9, 39-43.
69.
Shytle, R.D., Silver, A.A., Wilkinson, B.J., & Sanberg, P.R. (2002). A pilot controlled trial of transdermal nicotine in the treatment of attention deficit hyperactivity disorder. World Journal of BiologicalPsychiatry, 3, 150-155.
70.
Silva, R.R., Munoz, D.M., & Alpert, M. (1996). Carbamazepine use in children: Adolescents with features of attention-deficit hyperactivity disorder: A meta-analysis. The American Academy of Child and Adolescent Psychiatry, 35(3), 352-358.
71.
Simeon, J., Ferguson, H., & Van Wyck Fleet, J. (1986). Bupropion effects in attention deficit and conduct disorders. Canadian Journal of Psychiatry, 31, 581-585.
72.
Snyder, R., Turgay, A., Aman, M., Binder, C., Fisman, S., & Carroll, A. (2002). Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 1026-1036.
73.
Spencer, T., & Biederman, J. (2002). Non-stimulant treatment for attention-deficit/hyperactivity disorder. Journal of Attention Disorders, 6(1), 109-119.
74.
Spencer, T., Biederman, J., Coffey, B., Geller, D., Crawford, M., Bearman, S., et al. (2002). A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Archives of General Psychiatry,59, 649-657.
75.
Spencer, T., Biederman, J., Wilens, T., Steingard, R., & Geist, D. (1993). Nortriptyline treatment of children with attention-deficit hyperactivity disorder and tic disorder or Tourette's syndrome. Journal of the American Academy of Child and Adolescent Psychiatry, 32, 205-210.
76.
Swanson, J., Flockhart, D., Udrea, D., Cantwell, D., Connor, D., & Williams, L. (1995). Clonidine in the treatment of ADHD: Questions about safety and efficacy. Journal of Child and Adolescent Psychiatry, 5, 301-304.
77.
Taylor, E., Asherson, P., Banaschewski, T., Buitelaar, J., Coghill, D., Dopfner, M., et al. (2004). Clinical guidelines for hyperkinetic disorder . European Child and Adolescent Psychiatry, 13(Suppl. 1), 17-130.
78.
Thapar, A., Fowler, T., Rice, F., Scourfield, J., van den Bree, M., Thomas, H., et al. (2003). Maternal smoking during pregnancy and attention deficit hyperactivity disorder symptoms in offspring. American Journal of Psychiatry, 160, 1985-1989.
79.
Tourette's Syndrome Study Group. (2002). Treatment of ADHD in children with tics: A randomized controlled trial. Neurology, 58(4), 527-536.
80.
Upadhyaya, H., Brady, K., Sethurraman, G., Sonne, S., & Malcolm, R. (2001). Venlafaxine treatment of patients with comorbid alcohol/ cocaine abuse and attention-deficit hyperactivity disorder: A pilot study. Journal of Clinical Psychopharmacology, 21, 116-118.
81.
U.S. Food and Drug Administration. (2004). FDA launches a multi-pronged strategy to strengthen safeguards for children treated with antidepressant medication. Retrieved from http://www.fda.gov/bbs/topics/news/2004/NEW01124.html
82.
Varley, C.K., & McClellan, J. (1997). Case study: Two additional sudden deaths with tricyclics antidepressants. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 390-394.
83.
Velcea, G., & Winsberg, B. (2004). Atomoxetine and nonresponders to stimulants. American Journal of Psychiatry, 161, 1718-1719.
84.
Wernicke, J., Douglass, F., Girod, D., Jeffrey, B., Haitao, G., Kelsey, D., et al. (2003). Cardiovascular effects of atomoxetine in children, adolescents and adults. Drug Safety, 26, 729-741.
85.
Wigal, S., Wigal, T., McGough, J., McCracken, J., Kollins, S., Biederman, J., et al. (2005). A laboratory school comparison of mixed amphetamine salts extended release (Adderall XRReg.) and atomoxetine (StratteraReg) in school-aged children with attention deficit/hyperactivity disorder. Journal of Attention Disorders, 9, 275-289.
86.
Wilens, T.E., Biederman, J., Geist, D.E., Steingard, R., & Spencer, T. (1993). Nortriptyline in the treatment of ADHD: A chart review of 58 cases. Journal of the American Academy of Child and Adolescent Psychiatry, 32, 343-350.
87.
Wilens, T., Biederman, J., & Spencer, T. (1994). Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 33, 424-426.
88.
Wilens, T.E., Biederman, J., Spencer, T.J., Bostic, J., Prince, J., Monuteaux, M.C., et al. (1999). A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. The American Journal of Psychiatry, 156, 1931-1937.
89.
Wilens, T.E., Biederman, J., Wong, J., Spencer, T.J., & Prince, J.B. (2000). Adjunctive donepezil in attention deficit hyperactivity disorder youth: Case series. Journal of Children and Adolescents ofPsychopharmacology, 10, 217-222.
90.
Wilens, T.E., & Spencer, T.J. (1999). Debate: Combining methylphenidate and clonidine: A clinically sound medication option. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 614-622.
